Rise Advisors LLC Acquires New Shares in Bruker Co. (NASDAQ:BRKR)

Rise Advisors LLC acquired a new stake in Bruker Co. (NASDAQ:BRKR) in the first quarter, according to its most recent filing with the SEC. The fund acquired 287 shares of the medical research company’s stock, valued at approximately $27,000.

Other hedge funds have also bought and sold shares of the company. Sequoia Financial Advisors LLC purchased a new position in Bruker in the 4th quarter valued at approximately $2,384,000. Lighthouse Investment Partners LLC purchased a new position in Bruker in the 4th quarter valued at approximately $3,366,000. Vaughan Nelson Investment Management L.P. grew its stake in Bruker by 62.5% in the 4th quarter. Vaughan Nelson Investment Management L.P. now owns 315,210 shares of the medical research company’s stock valued at $23,161,000 after buying an additional 121,201 shares in the last quarter. BNP Paribas Financial Markets grew its stake in Bruker by 79.4% in the 4th quarter. BNP Paribas Financial Markets now owns 188,201 shares of the medical research company’s stock valued at $13,829,000 after buying an additional 83,274 shares in the last quarter. Finally, Nomura Holdings Inc. purchased a new position in Bruker in the 4th quarter valued at approximately $5,593,000. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Bruker Stock Down 0.4 %

Shares of NASDAQ:BRKR opened at $66.54 on Friday. Bruker Co. has a 52-week low of $53.79 and a 52-week high of $94.86. The firm has a fifty day moving average of $73.67 and a 200 day moving average of $77.48. The firm has a market capitalization of $9.67 billion, a PE ratio of 24.20, a price-to-earnings-growth ratio of 2.51 and a beta of 1.25. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.91 and a current ratio of 1.81.

Bruker (NASDAQ:BRKR) last announced its earnings results on Thursday, May 2nd. The medical research company reported $0.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.07. Bruker had a net margin of 13.38% and a return on equity of 27.31%. The company had revenue of $721.70 million during the quarter, compared to analyst estimates of $729.88 million. During the same period in the previous year, the business earned $0.64 earnings per share. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. As a group, research analysts anticipate that Bruker Co. will post 2.66 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, June 17th. Shareholders of record on Monday, June 3rd were paid a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.30%. The ex-dividend date was Monday, June 3rd. Bruker’s dividend payout ratio is presently 7.27%.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on BRKR shares. StockNews.com lowered shares of Bruker from a “buy” rating to a “hold” rating in a research report on Tuesday, May 21st. Bank of America reduced their price target on shares of Bruker from $95.00 to $90.00 and set a “buy” rating for the company in a research report on Monday, May 20th. Stifel Nicolaus reduced their price target on shares of Bruker from $81.00 to $77.00 and set a “hold” rating for the company in a research report on Monday, May 20th. The Goldman Sachs Group boosted their price target on shares of Bruker from $66.00 to $74.00 and gave the company a “sell” rating in a research report on Wednesday, April 10th. Finally, Jefferies Financial Group started coverage on shares of Bruker in a research report on Monday, June 3rd. They set a “buy” rating and a $85.00 price target for the company. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $85.00.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.